KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Raw Materials (2016 - 2021)

Biomarin Pharmaceutical's Raw Materials history spans 12 years, with the latest figure at $75.3 million for Q3 2021.

  • For the quarter ending Q3 2021, Raw Materials rose 1.99% year-over-year to $75.3 million, compared with a TTM value of $75.3 million through Sep 2021, up 1.99%, and an annual FY2020 reading of $76.7 million, up 3.0% over the prior year.
  • Raw Materials for Q3 2021 was $75.3 million at Biomarin Pharmaceutical, down from $83.7 million in the prior quarter.
  • The five-year high for Raw Materials was $83.7 million in Q2 2021, with the low at $46.5 million in Q2 2018.
  • Average Raw Materials over 5 years is $65.3 million, with a median of $68.4 million recorded in 2019.
  • Year-over-year, Raw Materials soared 49.6% in 2018 and then decreased 4.42% in 2021.
  • Tracing BMRN's Raw Materials over 5 years: stood at $49.9 million in 2017, then soared by 49.6% to $74.6 million in 2018, then decreased by 0.23% to $74.4 million in 2019, then grew by 3.0% to $76.7 million in 2020, then decreased by 1.75% to $75.3 million in 2021.
  • Per Business Quant, the three most recent readings for BMRN's Raw Materials are $75.3 million (Q3 2021), $83.7 million (Q2 2021), and $78.6 million (Q1 2021).